146 related articles for article (PubMed ID: 2658824)
1. [Pharmacokinetics of new cisplatin analogues in experimental animals].
Fujita H; Okamoto M; Takao A
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1366-72. PubMed ID: 2658824
[TBL] [Abstract][Full Text] [Related]
2. [Present status of cisplatin (CDDP) analogues in Japan].
Majima H
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1373-8. PubMed ID: 2658825
[TBL] [Abstract][Full Text] [Related]
3. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
4. [Preclinical and clinical evaluation of toxicity and antitumor activity of cisplatin analogues].
Ariyoshi Y; Ota K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1379-85. PubMed ID: 2658826
[TBL] [Abstract][Full Text] [Related]
5. Transplacental passage of Pt after treatment with the new triamine complex cis-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N4]-chloride platinum (II) monohydrochloride monohydrate.
Ognio E; Chiavarina B; Caviglioli G; Lapide M; Viale M
Arch Toxicol; 2004 Oct; 78(10):584-8. PubMed ID: 15150682
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
7. [Experimental study on carboplatin toxicity--a comparison with cisplatin].
Suzuki K; Usami T; Sudoko H; Ohtawara Y; Tajima A; Kawabe K; Aso Y
Gan To Kagaku Ryoho; 1988 Jul; 15(7):2153-8. PubMed ID: 3293538
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.
van Hennik MB; van der Vijgh WJ; Klein I; Elferink F; Vermorken JB; Winograd B; Pinedo HM
Cancer Res; 1987 Dec; 47(23):6297-301. PubMed ID: 3315183
[TBL] [Abstract][Full Text] [Related]
9. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
[TBL] [Abstract][Full Text] [Related]
10. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
[TBL] [Abstract][Full Text] [Related]
11. Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections.
Terheggen PM; Floot BG; Scherer E; Begg AC; Fichtinger-Schepman AM; den Engelse L
Cancer Res; 1987 Dec; 47(24 Pt 1):6719-25. PubMed ID: 3315190
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics of SK & F 104864 in experimental animals. II. Tissue distribution].
Fujita H; Okamoto M; Takao A; Abe H; Ishii R; Arase H
Gan To Kagaku Ryoho; 1995 Oct; 22(12):1789-92. PubMed ID: 7574811
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of intravenously injected [3H]tetrachloro(D,L-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin) in mice.
Kido Y; Khokhar AR; Siddik ZH
Drug Metab Dispos; 1992; 20(5):673-8. PubMed ID: 1358571
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice.
Kido Y; Khokhar AR; Yoshida M; Thai GW; Siddik ZH
Drug Metab Dispos; 1994; 22(2):312-7. PubMed ID: 8013287
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
Harland SJ; Newell DR; Siddik ZH; Chadwick R; Calvert AH; Harrap KR
Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
[TBL] [Abstract][Full Text] [Related]
16. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.
Boven E; van der Vijgh WJ; Nauta MM; Schlüper HM; Pinedo HM
Cancer Res; 1985 Jan; 45(1):86-90. PubMed ID: 4038381
[TBL] [Abstract][Full Text] [Related]
17. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetics of carboplatin (CBDCA) and tissue concentration of platinum in gynecologic organs].
Fujiwara K; Miyagi Y; Hayase R; Yoshinouchi M; Kobashi Y; Kohno I; Sekiba K
Gan To Kagaku Ryoho; 1988 Jun; 15(6):1943-8. PubMed ID: 3289504
[TBL] [Abstract][Full Text] [Related]
19. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice.
Boughattas NA; Lévi F; Fournier C; Hecquet B; Lemaigre G; Roulon A; Mathé G; Reinberg A
J Pharmacol Exp Ther; 1990 Nov; 255(2):672-9. PubMed ID: 2243347
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat.
Vadiei K; Siddik ZH; Khokhar AR; al-Baker S; Sampedro F; Perez-Soler R
Cancer Chemother Pharmacol; 1992; 30(5):365-9. PubMed ID: 1505075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]